HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer
出版年份 2014 全文链接
标题
HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF CANCER
Volume 135, Issue 10, Pages 2462-2474
出版商
Wiley
发表日期
2014-04-07
DOI
10.1002/ijc.28880
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells
- (2015) Elisabeth J. Walsby et al. Oncotarget
- A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth
- (2013) Xiang Wang et al. ACTA PHARMACOLOGICA SINICA
- Inhibition of Rapamycin-Induced AKT Activation Elicits Differential Antitumor Response in Head and Neck Cancers
- (2013) P. Radhakrishnan et al. CANCER RESEARCH
- First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors
- (2013) C. Sessa et al. CLINICAL CANCER RESEARCH
- Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer
- (2013) Z. A. Wainberg et al. MOLECULAR CANCER THERAPEUTICS
- Negative regulation of mTOR activity by LKB1-AMPK signaling in non-small cell lung cancer cells
- (2012) Li-xia Dong et al. ACTA PHARMACOLOGICA SINICA
- Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
- (2012) A Naing et al. BRITISH JOURNAL OF CANCER
- JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer
- (2012) Adrian Britschgi et al. CANCER CELL
- Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
- (2012) Taru Muranen et al. CANCER CELL
- Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition
- (2012) Oliver Weigert et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype
- (2012) O. Giles Best et al. LEUKEMIA & LYMPHOMA
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells
- (2011) W. Fiskus et al. CLINICAL CANCER RESEARCH
- The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia
- (2011) L Willems et al. LEUKEMIA
- Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer
- (2011) Tsuyoshi Ueno et al. LUNG CANCER
- Rapamycin passes the torch: a new generation of mTOR inhibitors
- (2011) Don Benjamin et al. NATURE REVIEWS DRUG DISCOVERY
- Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen
- (2011) T Tauchi et al. ONCOGENE
- PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
- (2011) V Serra et al. ONCOGENE
- Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors
- (2011) A. Chakrabarty et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Unusual Nature of Recent Snowpack Declines in the North American Cordillera
- (2011) Gregory T. Pederson et al. SCIENCE
- mTOR Inhibition, the Second Generation: ATP-Competitive mTOR Inhibitor Initiates Unexpected Receptor Tyrosine Kinase-Driven Feedback Loop
- (2011) M. Keniry et al. Cancer Discovery
- mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
- (2011) V. S. Rodrik-Outmezguine et al. Cancer Discovery
- Targeting heat shock proteins in cancer
- (2010) Gaëtan Jego et al. CANCER LETTERS
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells
- (2009) Matthew M. Roforth et al. ANTI-CANCER DRUGS
- Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
- (2009) Juan M. García-Martínez et al. BIOCHEMICAL JOURNAL
- AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
- (2009) C. M. Chresta et al. CANCER RESEARCH
- The upgraded role of HER3 and HER4 receptors in breast cancer
- (2009) Angelos K. Koutras et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma
- (2009) Martin Kaiser et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Tanespimycin: the opportunities and challenges of targeting heat shock protein 90
- (2009) Charles Erlichman EXPERT OPINION ON INVESTIGATIONAL DRUGS
- S9, a Novel Anticancer Agent, Exerts Its Anti-Proliferative Activity by Interfering with Both PI3K-Akt-mTOR Signaling and Microtubule Cytoskeleton
- (2009) Chao Zhang et al. PLoS One
- Dual Targeting of HSC70 and HSP72 Inhibits HSP90 Function and Induces Tumor-Specific Apoptosis
- (2008) Marissa V. Powers et al. CANCER CELL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started